|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
This meta-analysis showed evidence that ELAC2 Ser217Leu and Ala541Thr polymorphisms were associated with prostate cancer risk, and might be low-penetrance susceptibility markers of prostate cancer.
|
20231859 |
2010 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Two non-synonymous single-nucleotide polymorphisms (SNPs), Ser217Leu and Ala541Thr, in the elaC homolog 2 (Escherichia coli) (ELAC2) gene have been related to prostate cancer risk in previous studies, though with inconsistent results.
|
18375959 |
2008 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
We produced recombinant human tRNase ZL's, which contain one to three amino-acid substitutions from three missense mutations (Ser217Leu, Ala541Thr, and Arg781His) that are associated with the occurrence of prostate cancer.
|
15863270 |
2005 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Two HPC2 gene missense variants, Ser217Leu (Leu217) and Ala541Thr (Thr541) have been associated with incident prostate cancer cases in some studies, but not in others.
|
14625808 |
2003 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The Ala541Thr polymorphism was not associated with risk, and neither variant was associated with more aggressive prostate cancer phenotypes.
|
14504198 |
2003 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The ELAC2 gene has been proposed to be a prostate cancer susceptibility gene and is being referred to as HPC2, in part because three case-control studies suggested that two common polymorphisms (Ser217Leu and Ala541Thr) are associated with risk.
|
12783937 |
2003 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser-->Leu 217) and (Ala-->Thr 541).
|
12373607 |
2002 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The recently identified prostate cancer susceptibility gene ELAC2 ( HPC2) harbors two common missense variants, a serine to leucine substitution at residue 217 (Leu217) and an alanine to threonine substitution at residue 541 (Thr541).
|
12522685 |
2002 |
|
rs5030739
|
|
Prostate carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The prevalence of the HPC2 Ala541Thr allele was similar in men with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%) (P = .83).
|
11254449 |
2001 |